Issue 5, 2017

2-Arylaminobenzothiazole-arylpropenone conjugates as tubulin polymerization inhibitors

Abstract

A new series of 2-arylaminobenzothiazole-arylpropenone conjugates 56(ar) was designed, synthesized and investigated for their cytotoxic potency against the various human cancer cell lines. Most of these conjugates exhibited cytotoxic activity and inhibited in vitro tubulin polymerization effectively. Conjugates 5d and 6d cause cell cycle blocks in the G2/M phase in HeLa cells and treatments with 5d and 6d manifested increased mRNA and protein levels of the G2/M marker, cyclin B1. Immunocytochemistry revealed loss of intact microtubule structure in cells treated with 5d and 6d. Western blot analysis revealed that these conjugates accumulate more tubulin in the soluble fraction. Moreover, the triggering of apoptotic cell death after mitotic arrest was investigated by studying their effect on Hoechst staining, mitochondrial membrane potential, ROS generation.

Graphical abstract: 2-Arylaminobenzothiazole-arylpropenone conjugates as tubulin polymerization inhibitors

Article information

Article type
Research Article
Submitted
11 Oct 2016
Accepted
05 Jan 2017
First published
07 Mar 2017

Med. Chem. Commun., 2017,8, 924-941

2-Arylaminobenzothiazole-arylpropenone conjugates as tubulin polymerization inhibitors

A. V. Subba Rao, B. B. Rao, S. Sunkari, S. P. Shaik, B. Shaik and A. Kamal, Med. Chem. Commun., 2017, 8, 924 DOI: 10.1039/C6MD00562D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements